Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jul 22.

Published in final edited form as: Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec 22;387(4):329–339. doi: 10.1007/s00210-013-0950-4

Fig. 4 — cAMP and IL-6 production in BSMC by GPCR agonists alone or with concurrent Fsk treatment. a: Cells were treated with 0.1 μM of the indicated drug with or without concurrent treatment with 0.1 μM Fsk for 10 min in the presence of 0.2 mM IBMX. cAMP was measured by EIA.. b: Cells were treated with 0.1 μM of the indicated drug with or without concurrent treatment with 0.1 μM Fsk. IL-6 in culture media was measured by ELISA following 24 h drug treatment. Mean ± SEM, n=3 * indicates p<.05 compared to single drug

Fig. 4 — cAMP and IL-6 production in BSMC by GPCR agonists alone or with concurrent Fsk treatment. a: Cells were treated with 0.1 μM of the indicated drug with or without concurrent treatment with 0.1 μM Fsk for 10 min in the presence of 0.2 mM IBMX. cAMP was measured by EIA.. b: Cells were treated with 0.1 μM of the indicated drug with or without concurrent treatment with 0.1 μM Fsk. IL-6 in culture media was measured by ELISA following 24 h drug treatment. Mean ± SEM, n=3 * indicates p<.05 compared to single drug